Status:
RECRUITING
68Ga-XACP3 PET/CT in Prostate Cancer
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Conditions:
Prostate Cancer
PET/CT
Eligibility:
MALE
18-80 years
Phase:
NA
Brief Summary
The objective of the study is to construct a noninvasive approach 68Ga-XACP3 PET/CT to detect tumor lesions in patients with prostate cancer and to compare with 68Ga-PSMA PET/CT.
Detailed Description
As a new ACP3 targeting PET radiotracer, 68Ga-XACP3 is promising as an excellent imaging agent applicable to prostate cancer. In this research, subjects with prostate cancer or highly suspected recurr...
Eligibility Criteria
Inclusion Criteria:
- Adult patients (aged 18 years or older);
- Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report);
- Patients who had scheduled both standard-of-care imaging (68Ga-PSMA PET/CT) and 68Ga-XACP3 PET/CT scans;
- Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria:
- The inability or unwillingness of the research participant or legal representative to provide written informed consent.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT07242014
Start Date
September 1 2025
End Date
October 1 2027
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361000